The UK NCRI AML19 trial randomized 189 younger adults (median age 56) with newly diagnosed adverse cytogenetic AML or high-risk MDS to receive either CPX-351 or FLAG-Ida. Here, IDUA is linked to myelodysplastic syndrome.